Skip header and navigation

18 records – page 1 of 1.

Date Research Question / Title Unique ID Research Team
June 6, 2022 What is known about hybrid immunity to COVID-19? INF220501 RR Table Infectious Disease
June 6, 2022 What is known about hybrid immunity to COVID-19? INF220501 RR Infectious Disease
May 24, 2022 When should post-COVID infected patients receive booster shots? EOC220503 RR Table EOC
May 24, 2022 When should post-COVID infected patients receive booster shots? EOC220503 RR EOC
March 10, 2022 What is the safety/efficacy of the Novavax COVID-19 vaccine? EOC220302 RR Table EOC
March 10, 2022 What is the safety/efficacy of the Novavax COVID-19 vaccine? EOC220302 RR EOC
February 4, 2022 What are the harmful/adverse effects of multiple doses of COVID-19 mRNA vaccines? EOC220103 RR Table EOC
February 4, 2022 What are the harmful/adverse effects of multiple doses of COVID-19 mRNA vaccines? EOC220103 RR EOC
October 7, 2021 What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? EOC210902 RR Table EOC
October 7, 2021 What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? EOC210902 RR EOC
April 21, 2021 What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? EOC210302 RR EOC
April 21, 2021 What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? EOC210302 RR Table EOC
January 22, 2021 What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? [Update] EOC062201v2 RR EOC
January 22, 2021 What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? [Update] EOC062201v2 RR Table EOC
May 19, 2020 What are the risk factors for severity and death associated with COVID-19? EPM050901 RR Epidemiology & Modelling
May 19, 2020 Risk estimates for clinical factors predicting severity and/ or mortality associated with COVID-19 EPM050901 RR Table Epidemiology & Modelling
May 19, 2020 What is the relationship between antibody development and viral shedding and infectiousness? [Update] LAB041601v2 RR Laboratory
May 8, 2020 What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? [Update] LAB040701v2 RR Laboratory

18 records – page 1 of 1.